

Supplementary Table 3. Characteristics of included studies in key question #3

| Studies | Population | Age, yr | Sex (M/F) | Follow-up, yr | Outcome | Grade | Incidence of gastric neoplasm |
|---|--|---------|-----------|---------------|---------|--------------|-------------------------------|
| Capelle et al. ³¹ (2010) | 125 patients previously diagnosed with IM or dysplasia | 61 | 69/56 | 6 | 2 HGD | OLGA 0-II | 0/95 |
| | | | | | | OLGA III-IV | 2/30 |
| | | | | | | OLGIM 0-II | 0/96 |
| | | | | | | OLGIM III-IV | 2/29 |
| Rugge et al. ³² (2010) | 93 dyspeptic patients | 55 | 48/45 | 12 | 1 HGD | OLGA 0-II | 0/83 |
| | | | | | 2 GC | OLGA III-IV | 3/10 |
| Rugge and Genta ³³ (2018) | 7436 patients | 54 | 3330/4106 | 6.3 | 4 HGD | OLGA 0-II | 3/7261 |
| | | | | | 7 GC | OLGA III-IV | 8/175 |
| Rugge et al. ³⁴ (2019) | 1755 patients with dyspepsia | 52.7 | 789/966 | 4.6 | 1 HGD | OLGA 0-II | 0/1703 |
| | | | | | 2 GC | OLGA III-IV | 3/52 |
| den Hollander et al. ³⁵ (2019) | 279 patients with AG, IM or dysplasia | 57.9 | 137/142 | 4.8 | 1 HGD | OLGA 0-II | 2/135 |
| | | | | | 3 GC | OLGA III-IV | 2/55 |
| Nieminen et al. ³⁶ (2020) | 1137 male smokers with low PGI <25 | 64.1 | 1137/0 | 13.7 | 28 GC | OLGA 0-II | 22/963 |
| | | | | | | OLGA III-IV | 6/174 |
| | | | | | | OLGIM 0-II | 19/925 |
| | | | | | | OLGIM III-IV | 9/215 |
| Piazuelo et al. ³⁷ (2021) | 800 adults with precancerous lesions | 51 | 364/436 | 20 | 1 HGD | OLGA 0-II | 1/191 |
| | | | | | 11 GC | OLGA III-IV | 11/69 |
| | | | | | | OLGIM 0-II | 5/258 |
| | | | | | | OLGIM III-IV | 7/26 |

GC, gastric cancer; HGD, high-grade dysplasia; IM, intestinal metaplasia; OLGA, Operative Link of Gastritis Assessment; OLGIM, Operative Link of Gastric Intestinal Metaplasia assessment; PG, pepsinogen.